Nemo Healthcare

What Nemo Healthcare does

Nemo Healthcare is a Dutch medical technology company founded in 2010 that develops non-invasive electrophysiology-based systems for fetal and maternal monitoring during pregnancy. The company originated from a perinatal research collaboration between Máxima Medisch Centrum Veldhoven (MMC) and Eindhoven University of Technology (TU/e) dating back to the 1980s, and was formally established to commercialize electrophysiological monitoring technology developed through more than a decade of academic research. It is headquartered in Veldhoven, Netherlands, with a headcount of 1-10 employees.

The company's core technology uses a six-electrode abdominal patch (Nemo Patch) to capture fetal ECG, maternal ECG, and uterine EMG signals, which are processed via proprietary patented algorithms for maternal ECG cancellation and fetal QRS detection and transmitted wirelessly via the Nemo Link to a Nemo Base station. The product portfolio comprises two CE-approved commercial offerings: the Nemo Fetal Monitoring System (NFMS) for hospital use, launched at the end of 2018, and NemoRemote for home monitoring via an iPad app with guided self-application, launched in 2022. Clinical validation reports 86.8% reliability for fetal heart rate (versus 62-73% for Doppler ultrasound) and 89.5% sensitivity for uterine activity (versus 65.3% for tocodynamometry), with performance maintained independent of maternal BMI.

Nemo Healthcare sells directly to hospitals through an enterprise field sales model, supported by a Benelux-focused sales manager and implementation specialists who provide on-site training, technical integration, and trial placements. Revenue derives from hardware sales of the Nemo Patch, Nemo Link, and Nemo Base, alongside professional services including training, implementation support, and e-learning modules, under multi-year contracts with a two-year standard warranty. The company operates in five European countries (Netherlands, Germany, Austria, Belgium, Denmark), has secured approximately €4 million in EU Horizon 2020 SME Instrument Phase 2 funding alongside private investor rounds in 2011 and 2016, and is led by co-CEO Will Ickenroth with founders Chris Peters (CTO) and Rik Vullings (CSO).

Name

Nemo Healthcare

Legal name

Nemo Healthcare

Website

https://nemohealthcare.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Nemo Healthcare is a Dutch medical technology company that develops non-invasive electrophysiology-based systems for fetal and maternal pregnancy monitoring. Founded in 2010, it sells CE-approved hardware and home-monitoring solutions directly to hospitals across five European countries.

Ownership category

akta.pro rank

Product category

Fetal Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)

akta.pro secondary industries

Maternal & Neonatal Remote Monitoring Platforms (HLACAFAC), Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring) (HLALAHAC), Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG)

Keywords

• Fetal monitoring devices
• Pregnancy monitoring technology
• Non-invasive electrophysiology
• Maternal health monitoring
• Obstetric medical hardware

Headquarters

HQ city

Veldhoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Device Sales (Hardware): Sale of Nemo Fetal Monitoring System (NFMS) and NemoRemote hardware to hospitals. Products include Nemo Patch (electrodes), Nemo Link (wireless transmitter), and Nemo Base (processing unit). Systems are CE-approved medical devices.
2. Professional Services & Training: On-site training, implementation support, and system integration services provided to hospitals. Includes online training via MS Teams, on-site training, e-learning modules, and trial placements. Implementation typically takes 2-4 weeks.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Nemo Healthcare develops and sells non-invasive electrophysiology-based fetal and maternal monitoring systems. Its flagship Nemo Fetal Monitoring System (NFMS) is used in hospitals, while the NemoRemote solution enables home-based pregnancy monitoring via a connected iPad application paired with wireless abdominal patches.

Product overview

Nemo Healthcare offers a portfolio of two main commercial products for pregnancy monitoring: the Nemo Fetal Monitoring System (NFMS) for hospital use and NemoRemote for home monitoring. Both products are based on non-invasive electrophysiological technology that measures fetal ECG, maternal ECG, and uterine EMG through electrodes placed on the mother's abdomen. The systems include a 6-electrode Nemo Patch worn by the patient, a wireless Nemo Link transmitter, and a Nemo Base station with proprietary algorithms for signal processing and filtering. The company originated from PUREtrace technology developed in 2011 for uterine monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Nemo Fetal Monitoring System (NFMS): Wireless, non-invasive monitoring system for hospitals that measures fetal heart rate, maternal heart rate, and uterine activity using electrophysiological signals via a 6-electrode patch.
• NemoRemote
• PUREtrace

Products and services

• Nemo Fetal Monitoring System (NFMS)

Quantifiable outcome

• 89.5% sensitivity for uterine activity vs 65.3% for external tocodynamometry (gold standard: intra-uterine pressure catheter)
• +4 more outcomes

Named customers3 records

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Máxima Medisch Centrum Veldhoven (MMC)coreStrategic or Co-development PartnerFounding research partner and clinical collaborator. MMC and TU/e began joint research in the 1980s on hemodynamics of newborns in the NICU, expanding in 2000 to fetal heart activity analysis. MMC served as the founding clinical partner when Nemo Healthcare was established in 2010, originating from this collaboration.
• TU/e Eindhoven (Eindhoven University of Technology)coreStrategic or Co-development PartnerCo-founding academic partner with MMC. TU/e contributed advanced signal processing techniques and continued as a development partner through the company's formation and product commercialization.
• University Hospital Antwerp (UZA)coreStrategic or Co-development PartnerLaunch partner for clinical deployment of Nemo Healthcare monitoring systems. Collaborates in validation and clinical use of the technology.
• Hospitals in the Netherlands, Germany, Austria, and BelgiumminorStrategic or Co-development PartnerNetwork of hospitals using Nemo systems daily for clinical care and contributing to ongoing validation and improvement of the technology.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Philips: Philips is a global leader in patient monitoring and obstetric care, selling the Avalon fetal/maternal monitor series directly into the same European hospitals Nemo targets. It is a broad incumbent with overlapping CTG and remote monitoring capabilities, but as part of a much wider portfolio rather than a focused niche.
• GE Healthcare: GE Healthcare offers the Corometrics and Maternal-Infant Care fetal monitoring product lines, plus the former Monica Healthcare fECG technology it acquired. It is a direct technology competitor and broad incumbent whose installed base spans the same European and global hospitals Nemo targets.
• Mindray: Mindray manufactures the BeneFusion and ePM patient monitor lines including fetal monitoring modules, selling globally at lower price points. It is a broad incumbent competing on price in similar European and emerging-market hospital channels.
• Edan Instruments: Edan Instruments produces the F Series fetal and maternal monitors sold in Europe and globally. It is a broad incumbent competing with Nemo on price across similar hospital channels, particularly in mid-tier European and international markets.
• CooperSurgical: CooperSurgical supplies a broad portfolio of women's health and obstetric products, including fetal monitoring accessories and partner devices. It is a broad incumbent in the OB/women's health space with overlapping customer relationships in hospitals.
• Medtronic (formerly Covidien): Medtronic offers patient monitoring platforms that include maternal/fetal monitoring modules and serves the same European hospital channels as Nemo. It is a broad incumbent with overlapping capabilities embedded in a much larger medtech portfolio.

Direct peers

• Huntleigh Healthcare: Huntleigh (a part of Arjo) sells Sonicaid fetal monitors and cardiotocographs into European maternity hospitals, directly competing with Nemo's NFMS. It is the closest direct peer in terms of product category, customer base, and geographic focus.
• Neoventa Medical: Neoventa Medical offers the STAN (ST Analysis) fetal monitoring system, which is used alongside or integrated with CTG for intrapartum monitoring. It is a direct niche peer focused on the same clinical use case of advanced fetal monitoring during labor.
• Monica Healthcare: Monica Healthcare (now part of GE Healthcare) historically developed wireless fECG abdominal patch technology for fetal monitoring — directly comparable to Nemo's approach and the closest historical technology peer in the fECG category.

Emerging players

• PeriGen: PeriGen provides AI-powered perinatal decision support software that layers onto existing CTG/fetal monitors, addressing the same workflow gaps Nemo targets (CTG variability, maternal-fetal confusion). It is an emerging player whose analytics approach partially overlaps Nemo's signal-processing differentiation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights1 record

Customer concentration

• LinkedInlinkedin.com/company/nemo-healthcare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nemo Healthcare